Development of a human reactive astrocyte platform for drug discovery

 Astrocytes are one of the key glial types of the central nervous system (CNS) and play a critical role in maintaining brain homeostasis. Following CNS injury or in disease, astrocytes undergo a transformation to become ‘reactive’ and change their morphology and molecular profile, adopting different phenotypic states to respond to pathological insults. Reactive astrocytes participate in neuroinflammatory processes occurring in neurodegenerative diseases through secretion of neuro- and immune-modulatory factors. Recently, an in vitro reactive astrocyte model was developed using a stimulation cocktail of TNF-α, IL-1α, and Complement 1q (‘TIC’), which drives a neurotoxic state.¹ TIC-induced astrocytes have been shown to secrete growth factors, chemokines and pro-inflammatory cytokines, as well as neurotoxic lipids.

Poster





View the poster here







new board appointments
News
15 September 2026
Medicines Discovery Catapult appoints global life science and commercialisation leaders to its Board of Directors

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.


News
10 September 2026
Inspiring the next generation: Medicines Discovery Catapult scientist contributes to children’s science book 

Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.


News
03 September 2026
Medicines Discovery Catapult invests in UK biotech pioneers developing novel treatments for chronic diseases

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.





Medicines Discovery Catapult